Alpha-1 Antitrypsin Mutation in COVID Positive Patients Who Are Hospitalized

Overview

About this study

Patients with alpha-1 antitrypsin deficiency are prone to having an imbalance of lung Elastin degradation which render the patient's lung’s susceptible to inflammatory insults.  We have postulated that a severe COVID infection would accentuate this inflammatory imbalance and be more likely to lead the patient into a hospitalization event.  Our hypothesis would be to determine if this genetic mutation is found more frequently and patients who have been hospitalized with COVID.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients hospitalized with COVID as primary diagnosis.

 Exclusion Criteria:

  •  None.

Eligibility last updated 1/10/22. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Kensler Jackson, M.D.

Open for enrollment

Contact information:

Kensler Jackson M.D.

(904) 953-7095

Jackson.Kensler@mayo.edu

More information

Publications

Publications are currently not available